JPRN-UMIN000026575已完成2 期
The feasibility and efficacy of neoadjuvant FOLFOXIRI followed by laparoscopic surgery for locally advaned rectal cancer: A phase II study - nacFOLFOXIRI followed by LAP(NFL)
Osaka Medical College Hospital0 个研究点目标入组 58 人开始时间: 2017年3月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Requires continuous treatment with systtematic steroids 2)History of other malignancy with a disease-free interval<1years(other than curatively treated cutaneous basal cell carcinoma,curatively treated carcinoma in situ of the cervix,and gastroenterological cancer confirmed to be cured by endoscopic mucosal resection) 3)Active infections Pr evious palliative radiation therapy for bone metastasis or brain metastasis within 2 weeks 4)HBs antigen positive 5)Uncontrolled diarrhea,unstable angia,Uncontrolled diabetes mellitus 6)Serious complications 7)grade1 of neuropathy 8)Pregnant or lactating females,and males and fenales unwilling to use contraception 9)Psychiatric disability that would preclude study compliance 10)Otherwise determined by the investigator to be unsuitable for participation in the study
研究者
相似试验
已完成
4 期
A feasibility study of adjuvant therapy with FOLFOX plus Ca/Mg for the patient with colorectal cancerColorectal CancerJPRN-UMIN000003708Kyushu Study group of Clinical Cancer48
已完成
2 期
Feasibility study of neoadjuvant mFOLFOX6 plus cetuximab in patients with resectable liver limited metastases from colorectal cancer harboring KRAS wild typeMetastatic colorectal cancerJPRN-UMIN000007545ational Cancer Center Hospital East20
招募中
3 期
The (cost)effectiveness of neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine based chemoradiotherapy and adjuvant gemcitabine for (borderline) resectable pancreatic cancer.(borderline) resectable pancreatic cancer1001567410017991pancreatic cancerNL-OMON55463Erasmus MC, Universitair Medisch Centrum Rotterdam368
已完成
不适用
De (kosten)effectiviteit van neoadjuvante FOLFIRINOX versus neoadjuvante chemoradiotherapie met gemcitabine en adjuvante gemcitabine voor patiënten met (borderline) resectabel pancreaskanker - PREOPANC-2 studieResectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinomaNL-OMON28312Erasmus MC University Medical Center, Department of Surgery368
已完成
不适用
Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancerPancreatic cancerJPRN-UMIN000017718Department of Surgical Oncology, Nagoya University Graduate School of Medicine50